Literature DB >> 10192877

Multiple myeloma and related disorders. Lessons from an animal model.

J Radl1.   

Abstract

This short review of our own work presents two aspects of the studies on multiple myeloma (MM) in an animal model--the aging C57BL/KaLwRij mouse: 1. the immunological/biological aspect of the development of monoclonal B-cell proliferative disorders, the so-called monoclonal gammopathies (MG), and 2. the use of the mouse myeloma of the 5TMM lines for studies on the etiology/pathogenesis of MM and for developing new ways of treatment of this disease. Our research revealed that there are at least four major mechanisms in the development of MG. Many of the results were confirmed in clinical studies and lead to a new classification of MG according to their biology and possible pathogenesis. Most of MG can be classified into one of the following categories: 1. B-cell malignancies, 2. B-cell benign neoplasia, 3. MG due to an immunodeficiency with T/B cell imbalance, and 4. Antigen driven MG.

Entities:  

Mesh:

Year:  1999        PMID: 10192877

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  6 in total

1.  Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors.

Authors:  Maurizio Zangari; Tamara Berno; Ye Yang; Ming Zeng; Hongwei Xu; Lisa Pappas; Guido Tricot; Archana Kamalakar; Donghoon Yoon; Larry J Suva
Journal:  Bone       Date:  2013-12-31       Impact factor: 4.398

2.  Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma.

Authors:  Jo Caers; Dirk Hose; Ine Kuipers; Tomas Jan Bos; Els Van Valckenborgh; Eline Menu; Elke De Bruyne; Hartmut Goldschmidt; Ben Van Camp; Bernard Klein; Karin Vanderkerken
Journal:  Haematologica       Date:  2009-10-14       Impact factor: 9.941

3.  Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice.

Authors:  Wan Cheung Cheung; Joong Su Kim; Michael Linden; Liangping Peng; Brian Van Ness; Roberto D Polakiewicz; Siegfried Janz
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

Review 4.  Multiple myeloma cancer stem cells.

Authors:  Carol Ann Huff; William Matsui
Journal:  J Clin Oncol       Date:  2008-06-10       Impact factor: 44.544

5.  Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells.

Authors:  Junling Zhuang; Jianghong Zhang; Seint T Lwin; James R Edwards; Claire M Edwards; Gregory R Mundy; Xiangli Yang
Journal:  PLoS One       Date:  2012-11-16       Impact factor: 3.240

6.  A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease.

Authors:  Peter O Hofgaard; Henriette C Jodal; Kurt Bommert; Bertrand Huard; Jo Caers; Harald Carlsen; Rolf Schwarzer; Nicole Schünemann; Franziska Jundt; Mona M Lindeberg; Bjarne Bogen
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.